Biogen
BIIB
$205.99
-1.40%
Biogen is an established biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative and rare diseases, operating within the drug manufacturing industry. It holds a distinct competitive position as a pioneer in multiple sclerosis (MS) treatments, though its MS franchise is now declining, and it is actively pivoting toward high-growth areas like Alzheimer's disease, immunology, and rare diseases through acquisitions and pipeline development. The current investor narrative centers on Biogen's strategic transformation: recent acquisitions of Apellis and RayThera signal a shift into immunology and rare diseases, while the FDA approval of a high-dose Spinraza and mixed clinical trial results for its Alzheimer's drug diranersen have created both optimism and uncertainty about the company's growth trajectory.…
BIIB
Biogen
$205.99
Related headlines
Investment Opinion: Should I buy BIIB Today?
Rating: Buy. Thesis: Biogen's strong free cash flow generation, low forward P/E, and strategic pivot into immunology and rare diseases via acquisitions position it for earnings recovery, making it an attractive value play in the biopharma space. The analyst consensus is Buy with an average target of $225.45, implying 14.3% upside.
Supporting Evidence: Biogen's trailing P/E of 19.9x is below the sector median of ~22x, and its forward P/E of 11.9x is significantly lower, suggesting earnings growth is expected. Revenue grew 1.9% YoY in Q1 2026 to $2.48B, and the company generated $2.62B in trailing free cash flow, a FCF yield of ~10.2%. Gross margin of 73.3% is healthy, though down from 76.2% a year ago. The EV/EBITDA of 9.6x is reasonable. The stock has 14.3% upside to the average analyst target.
Risks & Conditions: The biggest risks are failure of the Alzheimer's drug diranersen to gain approval, continued MS franchise decline, and integration challenges from acquisitions. This Buy rating would be downgraded to Hold if revenue growth decelerates below 0% or if the forward P/E expands above 15x without earnings materializing. It would be upgraded if the Alzheimer's drug shows positive Phase 3 data or if revenue growth accelerates above 5%. Overall, Biogen appears undervalued relative to its forward earnings potential and FCF generation.
Sign up to view all
BIIB 12-Month Price Forecast
Biogen's outlook is cautiously bullish over the next 12 months. The stock's low forward P/E and strong FCF generation provide a valuation floor, while the strategic pivot into immunology and rare diseases offers upside optionality. However, execution risk is high given the declining MS franchise and pipeline uncertainty. The base case of gradual growth and margin stabilization is most likely, with the stock reaching the average target of $225. If pipeline catalysts succeed, the bull case of $300 is achievable. The stance would be upgraded to high confidence if diranersen shows positive Phase 3 data, and downgraded to neutral if revenue growth turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Biogen's 12-month outlook, with a consensus price target around $225.45 and implied upside of +9.4% versus the current price.
Average Target
$225.45
0 analysts
Implied Upside
+9.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$157 - $300
Analyst target range
Biogen is covered by 31 analysts, with a consensus recommendation of 'Buy' (mean recommendation 1.92 on a 1-5 scale where 1 is Strong Buy). The average target price is $225.45, implying approximately 14.3% upside from the current price of $197.24. The distribution shows a bullish lean, with recent upgrades from Truist Securities (Hold to Buy) and Needham (Hold to Buy) in June-July 2026, while Morgan Stanley and Citigroup maintain neutral ratings. The target price range spans from a low of $157.00 to a high of $300.00, indicating significant divergence in analyst views. The high target of $300 assumes successful pipeline execution, particularly for Leqembi and the immunology platform, along with margin expansion from cost synergies from the Apellis acquisition. The low target of $157 reflects concerns about the declining MS franchise, clinical trial risks (e.g., diranersen miss), and potential competitive pressure on Spinraza. The wide spread ($143) suggests high uncertainty about Biogen's growth trajectory, which is typical for a company undergoing a strategic transformation. The recent upgrade activity and the average target above the current price support a cautiously bullish outlook, but investors should be aware of the risks implied by the low-end estimates.
Bulls vs Bears: BIIB Investment Factors
Biogen presents a mixed investment case. On the bull side, the company generates strong free cash flow ($2.62B TTM), has a forward P/E of 11.9x implying earnings recovery, and enjoys analyst consensus Buy with 14.3% upside to the average target. Strategic acquisitions into immunology and rare diseases diversify away from the declining MS franchise. On the bear side, the MS franchise continues to shrink, margins are compressing (operating margin down from 30.1% to 16.0% YoY), and the Alzheimer's drug trial miss adds pipeline uncertainty. The single most important tension is whether the new product portfolio (Leqembi, Skyclarys, Apellis drugs) can accelerate revenue growth enough to offset MS declines and justify the current valuation. Currently, the bull case has slightly stronger evidence given the strong FCF and low forward P/E, but execution risk remains high.
Bullish
- Strong free cash flow generation: Biogen generated $696.7M in FCF in Q1 2026 and $2.62B in trailing twelve months, yielding a FCF yield of approximately 10.2%. This provides ample liquidity for acquisitions and internal investment, supporting the strategic pivot.
- Forward P/E implies earnings recovery: The forward P/E of 11.9x is significantly lower than the trailing P/E of 19.9x, suggesting the market expects substantial earnings growth. Estimated EPS of $20.92 for the next year would represent a sharp rebound from the current run rate, driven by cost synergies from acquisitions and new product revenue.
- Analyst consensus Buy with upside: With 31 analysts covering the stock, the consensus is Buy (mean recommendation 1.92) and the average target price of $225.45 implies 14.3% upside from the current $197.24. Recent upgrades from Truist and Needham in June-July 2026 add momentum.
- Strategic acquisitions diversify pipeline: The acquisitions of Apellis (completed May 2026) and RayThera (announced June 2026) expand Biogen into immunology and rare diseases, reducing reliance on the declining MS franchise. Apellis adds two fast-growing drugs, while RayThera targets a $112B immunology market.
Bearish
- Declining MS franchise revenue: MS product revenues totaled only $957.5M in Q1 2026, representing about 39% of total revenue, down from 40% in 2025. This core segment is in structural decline, and new products like Leqembi and Skyclarys have not yet offset the decline, with overall revenue growth of just 1.9% YoY.
- Margin compression and earnings volatility: Gross margin fell from 76.2% in Q1 2025 to 73.3% in Q1 2026, while operating margin dropped from 30.1% to 16.0% over the same period. Net income swung from a $48.4M loss in Q4 2025 to $319.5M profit in Q1 2026, highlighting inconsistency.
- Alzheimer's drug trial miss creates uncertainty: In May 2026, Biogen's Alzheimer's drug diranersen missed its primary endpoint in a clinical trial, causing a sharp selloff. Although secondary data showed promise, the miss raises doubts about the pipeline's near-term potential and could delay revenue contributions from this high-profile asset.
- High valuation on trailing earnings: The trailing P/E of 19.9x is above the sector median of around 22x? Actually it's slightly below, but the stock's EV/EBITDA of 9.6x is reasonable. However, the PEG ratio is negative (-0.95) due to negative earnings growth expectations, indicating that the current valuation may not be supported if earnings fail to recover.
BIIB Technical Analysis
Biogen is in a strong recovery uptrend, with the stock up 54.7% over the past year, significantly outperforming the S&P 500's 20.9% gain. The current price of $197.24 sits at 71.5% of its 52-week range ($121.05–$219.72), indicating the stock is in the upper half of its range but not yet at overbought extremes. This positioning suggests sustained bullish momentum with room for further upside, though it is not without risk of mean reversion. Over the past three months, Biogen has gained 12.1%, while the one-month change is -0.7%, showing a short-term pullback that contrasts with the strong longer-term trend. This divergence could signal a temporary consolidation or profit-taking after the stock surged from around $190 in mid-June to a peak of $216.63 on June 29, followed by a retreat. The relative strength versus the S&P 500 over one month is -1.3%, indicating underperformance recently, but the three-month relative strength of +5.8% confirms the medium-term uptrend remains intact. The 52-week low of $121.05 provides a clear support level, while the 52-week high of $219.72 acts as resistance. A breakout above $219.72 would signal a continuation of the uptrend, potentially targeting new highs, while a breakdown below $121.05 would be a severe bearish signal, though unlikely given the current price. Biogen's beta of 0.158 is extremely low, meaning the stock is far less volatile than the market—a 1% move in the S&P 500 would be expected to move Biogen by only about 0.16%. This low beta suggests the stock's movements are driven more by company-specific factors than broad market swings, which can be attractive for risk-averse investors but may also limit upside in strong market rallies.
Beta
0.16
0.16x market volatility
Max Drawdown
-14.3%
Largest decline past year
52-Week Range
$121-$220
Price range past year
Annual Return
+60.1%
Cumulative gain past year
| Period | BIIB Return | S&P 500 |
|---|---|---|
| 1m | +3.7% | +0.3% |
| 3m | +16.1% | +4.7% |
| 6m | +25.3% | +7.5% |
| 1y | +60.1% | +18.4% |
| ytd | +15.8% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BIIB Fundamental Analysis
Biogen's revenue trajectory shows modest growth with some volatility. In Q1 2026, revenue was $2.478 billion, up 1.9% year-over-year from $2.431 billion in Q1 2025. However, looking at the trailing four quarters, revenue has fluctuated: Q2 2025 was $2.646 billion, Q3 2025 was $2.455 billion, Q4 2025 was $2.279 billion, and Q1 2026 rebounded to $2.478 billion. The decline in Q4 2025 was partly due to a net loss that quarter. Revenue segments show that MS product revenues (including Fumarate, Interferon, and TYSABRI) totaled $957.5 million, while Spinraza contributed $374 million. The growth is being driven by newer products like Leqembi (Alzheimer's) and Skyclarys (Friedreich's ataxia), but the declining MS franchise remains a headwind. The overall growth rate is modest, and the investment case hinges on whether new launches can accelerate revenue growth. Biogen is profitable, with net income of $319.5 million in Q1 2026, though it posted a net loss of -$48.4 million in Q4 2025 due to one-time charges. Gross margin in Q1 2026 was 73.3%, down from 76.2% in Q1 2025, indicating some margin compression. Operating margin was 16.0% in Q1 2026, down from 30.1% in Q1 2025, reflecting higher operating expenses. The net margin of 12.9% in Q1 2026 is healthy but below the 23.9% seen in Q2 2025. The company's profitability is solid but has been inconsistent, and margins are under pressure from R&D spending ($573 million in Q1 2026) and acquisition-related costs. Biogen has a strong balance sheet with a current ratio of 2.68 and a debt-to-equity ratio of 0.38, indicating low financial leverage. Free cash flow (FCF) was $696.7 million in Q1 2026, and trailing twelve-month FCF is $2.623 billion, providing ample liquidity for internal investment and acquisitions. The company generated $645.5 million in operating cash flow in Q1 2026, and capital expenditures were only $51.2 million, so it is self-funding. Return on equity (ROE) is 7.1%, which is modest but acceptable for a mature biopharma. The strong FCF yield (FCF/market cap) of approximately 10.2% suggests the stock is reasonably valued on a cash flow basis.
Quarterly Revenue
$2.5B
2026-03
Revenue YoY Growth
+1.9%
YoY Comparison
Gross Margin
73.3%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BIIB Overvalued?
Since Biogen has positive net income ($319.5 million in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 19.9x, while the forward P/E is 11.9x, based on estimated EPS of $20.92. The large gap between trailing and forward P/E implies the market expects significant earnings growth in the coming year, likely driven by cost savings from acquisitions and revenue from new products. Compared to the industry average (Drug Manufacturers - General), Biogen's trailing P/E of 19.9x is at a discount to the sector median of around 22x, but the forward P/E of 11.9x is significantly lower, suggesting the market is pricing in a recovery in earnings. The EV/EBITDA of 9.6x is also reasonable for the sector. Historically, Biogen's trailing P/E has ranged from about 7x to 38x over the past five years. The current 19.9x is near the middle of that range, indicating it is not at extreme levels. The P/E was as low as 7.2x in Q2 2025 and as high as 37.6x in Q4 2023. The current level suggests the market is cautiously optimistic but not overly exuberant. The price-to-book ratio of 1.41x is near the lower end of its historical range (1.1x to 4.8x), which could indicate value, but book value is less relevant for a biotech with significant intangible assets. Overall, Biogen appears reasonably valued relative to its own history and the sector, with the forward P/E suggesting upside if earnings materialize.
PE
19.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Biogen's financial health is mixed. While the company has a strong balance sheet with a debt-to-equity ratio of 0.38 and a current ratio of 2.68, its earnings are volatile. Net income swung from a loss of -$48.4M in Q4 2025 to a profit of $319.5M in Q1 2026, and operating margin fell from 30.1% to 16.0% year-over-year. The company's revenue growth is modest at 1.9% YoY, and gross margin declined from 76.2% to 73.3%. High R&D spending ($573M in Q1 2026) and acquisition-related costs pressure profitability. The reliance on the declining MS franchise (40% of revenue) and the need for new products to ramp up create operational risk.
Market & Competitive Risks: Biogen faces valuation risk if earnings do not recover as expected. The trailing P/E of 19.9x is near the middle of its historical range (7x-38x), but the forward P/E of 11.9x implies significant earnings growth that may not materialize. The stock's beta of 0.158 is extremely low, meaning it is less correlated with the market, but this also limits upside in strong market rallies. Competitive threats include new MS treatments from other companies and potential competition for Spinraza from gene therapies. Regulatory risk is present for Alzheimer's drugs and other pipeline assets. The wide range of analyst targets ($157-$300) highlights high uncertainty.
Worst-Case Scenario: The worst case would involve a combination of factors: continued decline in MS revenue, failure of key pipeline drugs (e.g., diranersen misses entirely, RayThera assets fail), and inability to integrate Apellis successfully, leading to margin erosion and negative earnings. In this scenario, the stock could fall to the 52-week low of $121.05, representing a 38.6% decline from the current price of $197.24. This would imply a P/E of about 12x on depressed earnings, which is not unprecedented given the stock's historical low of 7.2x in Q2 2025.
FAQ
The key risks are: 1) Pipeline risk: The Alzheimer's drug diranersen missed its primary endpoint in May 2026, and further failures could derail growth expectations. 2) Franchise decline: MS products, which contributed 40% of revenue in 2025, are in structural decline, and new products may not offset the drop quickly enough. 3) Margin pressure: Gross margin fell from 76.2% to 73.3% YoY, and operating margin dropped from 30.1% to 16.0%, indicating cost headwinds from acquisitions and R&D. 4) Valuation risk: If earnings do not recover, the stock could de-rate to a lower P/E multiple, potentially falling to the 52-week low of $121.05. The most severe risk is a combination of pipeline failure and accelerated MS decline, which could lead to a 38.6% loss from the current price.
The 12-month forecast is based on three scenarios. The base case (50% probability) expects gradual revenue growth and margin stabilization, with the stock reaching the average analyst target of $225, implying 14.3% upside. The bull case (25% probability) assumes successful pipeline execution and cost synergies, driving the stock to $300 (52% upside). The bear case (25% probability) involves pipeline failures and accelerated MS decline, pushing the stock to $157 (20% downside). The most likely scenario is the base case, supported by the low forward P/E and strong FCF, but the wide range reflects high uncertainty. Key assumptions include revenue growth of 2-4% and EPS of $20.92.
Biogen appears undervalued based on forward earnings and free cash flow. The forward P/E of 11.9x is a significant discount to the sector median of ~22x and to its own trailing P/E of 19.9x, implying the market expects earnings to recover. The EV/EBITDA of 9.6x is also reasonable. On a price-to-book basis, the 1.41x ratio is near the lower end of its historical range (1.1x-4.8x), suggesting value. However, the trailing P/E of 19.9x is near the middle of its 5-year range (7x-38x), so it is not deeply undervalued on a trailing basis. Overall, the market is pricing in a cautious outlook, and if earnings materialize as estimated, the stock is undervalued.
Biogen presents a compelling risk/reward for investors who can tolerate pipeline uncertainty. The stock trades at a forward P/E of 11.9x, well below the sector median of ~22x, and offers a free cash flow yield of about 10.2%. Analyst consensus is Buy with an average target of $225.45, implying 14.3% upside. However, the biggest downside risk is the declining MS franchise and the potential failure of key pipeline drugs like diranersen. For value-oriented investors with a 12-month horizon, Biogen is a good buy given the low valuation and strong cash flows. For growth investors seeking high revenue growth, it may be less attractive due to the modest 1.9% YoY revenue increase.
Biogen is best suited for a medium- to long-term investment horizon of 12-24 months. The stock's low beta of 0.158 means it is less volatile than the market, making it less attractive for short-term trading. The company pays no dividend, so total return depends on price appreciation. The earnings recovery story and pipeline catalysts (e.g., diranersen data, Leqembi ramp) are likely to play out over several quarters, favoring a longer holding period. Short-term traders may find the stock's recent pullback from $216 to $197 an opportunity, but the low volatility limits quick gains. A minimum holding period of 12 months is recommended to allow the strategic transformation to materialize.